



SciTech Development, LLC

**FOR IMMEDIATE RELEASE**


**SciTech Development to Present at 2020 NYC Spring Oncology Investor Conference**

(GROSSE POINTE FARMS, MI) March 3, 2020 – SciTech Development, a clinical stage drug development company, will deliver a corporate presentation and meet with investors at the NYC Spring Oncology Investor Conference 2020. The conference will take place March 31 - April 1, 2020 at 1155 6th Ave, 22<sup>nd</sup> Floor in New York City.



Presenting SciTech’s proprietary ST-001 nanoFenretinide technology at the conference will be Earle Holsapple (SciTech President) and Dr. Brian Leyland-Jones (SciTech Chief Medical Officer). Investors and interested parties are invited to request a meeting with SciTech Development during and after the conference through the One-on-One Meeting Space or via mobile phone: Earle Holsapple | +1-313-938-5517.

SciTech is seeking funding to bring its lead product ST-001 nanoFenretinide to market for the treatment of T-cell non-Hodgkin's lymphoma (NHL) and small cell lung cancer (SCLC). ST-001 may be used as a standalone drug or as an ancillary treatment with immunotherapy. SciTech’s product pipeline also includes treatment for several other cancer indications.

The FDA has accepted SciTech Development's IND Application for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). The FDA has granted Orphan Drug Status for ST-001 in the treatment of  nanoFenretinide™ two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | [eth@scitechdevelopment.com](mailto:eth@scitechdevelopment.com)

## About SciTech Development

SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit, Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Additional information regarding SciTech's nanoparticle technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at <https://www.scitechdevelopment.com/>.

## About The NYC Spring Oncology Investor Conference

The NYC Spring Oncology Investor Conference 2020, sponsored and organized by the National Foundation for Cancer Research (NFCR) and Perkins Coie, is the leading conference for early-stage private and public cancer investing. More information is available from the conference website (<https://www.oncologyinvestorconference.com/>).

**For More Information:** Earle T. Holsapple, President  
SciTech Development, LLC  
(313) 938-5517

## Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



####